• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Julie Reed on How the Biosimilars Forum Is Preparing for US Market Introduction of Adalimumab Biosimilar

Video

Julie M. Reed, the new executive director of the Biosimilars Forum, shares how the Forum is preparing for the US market introduction of the first FDA-approved adalimumab biosimilars.

Julie M. Reed, the new executive director of the Biosimilars Forum, shares how the Forum is preparing for the US market introduction of the first FDA-approved adalimumab biosimilars.

Transcript:

How will you and the Forum be preparing for the launches of the first FDA adalimumab biosimilars coming early next year?

I think most of the ones that are approved [were developed by] our members. And like interchangeability, we're going to do a lot of education on that. And I think that'll be one of our biggest preparations: the education, and monitoring, and watching for any misinformation. So, we're excited. Our members are excited. It's an industry, so we're excited to see how quickly we'll achieve those cost savings that you guys are predicting because we'd like to surpass your predictions and we think it could happen.

Related Videos
Lakesha Farmer from Cencora
Prerakkumar Parikh, PharmD
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, executive director of the Biosimilars Forum
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Related Content
© 2024 MJH Life Sciences

All rights reserved.